Latest News

June 16, 2023

Media Advisory: Nature Medicine publishes key lessons from NCI-MATCH to guide future precision medicine trials

June 1, 2023

Press Release: ComboMATCH investigators are translating robust pre-clinical evidence for new anti-cancer drug combinations into a series of early-phase clinical trials

May 31, 2023

NCI-MATCH named among five innovative oncology therapies changing the game

May 31, 2023

Your daily guide to ASCO 2023 research presentations by ECOG-ACRIN and PrECOG

May 30, 2023

Group leaders talk with The Cancer Letter about the cisplatin chemotherapy shortage (login required)

May 17, 2023

Press Release: ECOG-ACRIN announces the recipients of its 2023 scientific leadership and mentorship awards

May 11, 2023

Press Release: Historic achievement for the ongoing InPACT penile cancer trial—100 patients enrolled thus far, the most ever to a prospective study in this extremely rare disease

April 29, 2023

A TAILORx post hoc analysis is the first to show racial and ethnic differences in locoregional breast cancer recurrence

April 28, 2023

JAMA Surgery publishes TAILORx analysis showing that racial and ethnic differences in locoregional breast cancer recurrence patterns are prevalent even in a clinical trial population with similar access to care


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
41

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group